LOS ANGELES, CA--(Marketwire - February 18, 2009) - Cardo Medical (OTCBB: CDOM), a company
engaged in the development of orthopedic medical devices, announces the
femur-first versatility in surgical technique with its Uni-Compartmental
Knee System. Uni-compartmental knee arthroplasty procedures are most
commonly performed using tibial-first referencing surgical techniques;
however the Cardo Medical Uni-Compartmental Knee system also provides
surgeons with additional intra-operative versatility to easily adapt to
femur-first surgical techniques. Dr. Andrew Yun, an orthopedic surgeon at
St. John's Hospital in Santa Monica, CA, has performed numerous femur-first
uni-compartmental arthroplasty procedures and commented, "I have been very
satisfied with the ease of use and outcomes with this system. The Cardo
engineering team has been incredible to work with, and I have enjoyed the
responsiveness and quality of work which comes from this group." In
addition, Dr. Jonathan Braslow, an orthopedic surgeon at JFK Memorial
Hospital in Indio, CA, also stated, "The Cardo Align 360 instrumentation
system eliminates the guesswork for the first cut, the system was easy and
simple to use and creates a reproducible outcome each time." The Align 360
Uni-Compartmental Knee System, Cardo Medical's initial product release, has
been used successfully since its introduction in January 2007. System
enhancements for the femur-first approach include novel, unique femoral
tibial alignment ("knee jack") instruments with dedicated alignment and
resection guides.
Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo Medical,
stated, "The Cardo Medical Uni-Compartmental Knee system was our first
commercially available arthroplasty system, and also set the standards of
simplicity, versatility and reproducibility we design into all our system
offerings. The Align 360 Uni-Compartmental Knee system enables surgeons
the flexibility to choose between both a tibial-first or femoral-first
referencing and resection surgical technique and approach. With its
innovative alignment and conservative resection instrumentation, the system
easily adapts to any surgeons' training and methodology, including use with
mechanical or computer assisted surgical navigation. We are pleased to
offer intra-operative versatility within all of our systems and continue to
offer modularity and interchangeability, especially within our Align 360
knee platform. Our innovations especially with regards to instrumentation,
surgical approaches and techniques enable surgeons to achieve excellent
surgical outcomes."
About Cardo Medical, Inc.
Cardo Medical (OTCBB: CDOM) develops reconstructive orthopedic and spinal
surgery products through advanced engineering and focuses on product
development, marketing and distribution within the US market. Cardo
Medical's superior engineering talent closely collaborates with leading
surgeons around the country to create products that reduce or eliminate
joint pain and allow patients to achieve more active lives. The company's
cutting edge products are specifically developed with patients, surgeons
and OR staff in mind and are designed to reduce operative time, enhance
surgical technique, shorten hospital stays, reduce recovery time and
improve outcomes. Cardo Medical's product portfolio includes devices for
knee, hip, spinal fusion and motion preservation arthroplasty and
replacement, many of which have already received FDA clearance. Cardo
Medical has a robust and innovative product pipeline pending both USPTO and
FDA submission and clearance.
Cardo Medical works in small, focused development teams in concert with
physicians to rapidly develop products from concept to launch. We are
committed to exceeding the standards by which any device company is judged.
Please visit our website at www.cardomedical.com for more information on
the Align 360 Uni-Compartmental Knee System in addition to our portfolio of
other Reconstructive and Spinal Implant systems.
This press release contains "forward-looking statements," as that term is
defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
regarding product development efforts and other non-historical facts about
expectations, beliefs or intentions regarding the business, technologies
and products, financial condition, strategies or prospects. Many factors
could cause actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements. These
factors include those described in our filings with the Securities and
Exchange Commission, as well as risks inherent in funding, developing and
obtaining regulatory approvals of new, commercially-viable and competitive
products and treatments, including the risks that any products under
development may fail, may not achieve the expected results or effectiveness
and may not generate data that would support the approval or marketing of
products for the ailments being studied or for other ailments. In
addition, forward-looking statements also may be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the regulatory
process for new products and indications, manufacturing issues that may
arise, patent positions and litigation, among other factors. We do not
undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
